Retinoic acid (RA) is known to accelerate wound healing and induce cell differentiation. All-trans-RA (ATRA) exerts its effect by binding retinoic acid receptors (RARs), members of the nuclear receptor family. We investigated whether RA can alter expression of eotaxin, a potent eosinophil chemoattractant which is regulated by the transcription factors, signal transducer and activator of transcription 6 (STAT6) and nuclear factor-κB. We examined the effects of RA on eotaxin expression in a human bronchial epithelial cell line BEAS-2B. ATRA and its stereodimer 9-cis retinoic acid (9-cis RA) inhibited interleukin-4 (IL-4)-induced release of eotaxin at 10 -6 M by 78.0% and 52.0%, respectively (P<0.05). ATRA and 9-cis RA also significantly inhibited IL-4-induced eotaxin mRNA expression at 10 -6 M by 52.3% and 53.5%, respectively (P<0.05). In contrast, neither ATRA nor 9-cis RA had any effects on tumor necrosis factor-α-induced eotaxin production.
Introduction
Infiltration of eosinophils into the sites of inflammation is a hallmark of allergic diseases, such as bronchial asthma, and is mediated by several chemotactic factors, including eotaxin. Eotaxin was initially discovered using a biologic assay in guinea pigs designed to identify the molecules responsible for allergen-induced eosinophil accumulation in the lung (1) . Because eotaxin has been reported to be highly expressed in bronchoalveolar lavage from human asthmatics (2) and to be associated with airway hyperresponsiveness (3), it is thought to play an important role in the pathogenesis of bronchial asthma. A similar synergistic effect of TNF-α  and IL-4 in the induction of eotaxin mRNA and protein expression has been reported in airway epithelial cells (7) .
The sequence of the eotaxin promoter has been reported by two independent groups (8, 9) . Overlapping elements for signal transducer and activator of transcription 6 (STAT6) 2 and nuclear factor-κB (NF-κB) within the proximal eotaxin promoter has been shown to mediate the transcriptional induction by IL-4 and TNF-α in BEAS-2B cells (10).
Interleukin-13 also upregulates eotaxin expression by a STAT6-dependent mechanism in BEAS-2B cells (11) . Glucocorticoids inhibit eotaxin mRNA expression induced with IL-1β, IL-4 or TNF-α in epithelial cell lines (5, 7) . Other regulators of eotaxin expression include IL-5, which was reported to inhibit TNF-α-induced eotaxin expression in eosinophils (12) , and β 2 -agonists, which were reported to inhibit TNF-α-induced eotaxin release in human LCMP-00289-2003.R1 -4 - airway smooth muscle cells (13) .
Retinoic acid (RA) is an active metabolite of vitamin A and regulates a wide range of biological processes, including cell proliferation, differentiation and morphogenesis (14) .
Predominantly all-trans-retinoic acid (ATRA) and its stereodimer 9-cis retinoic acid (9-cis RA) were found to be very potent metabolites exerting pleiotropic effects. ATRA is clinically used for controlling keloid formation (15) and for treating acute promyelocytic leukemia (16) .
In the respiratory system, ATRA has been reported to reverse elastase-induced experimental emphysema in rats by Massaro et al. (17) . Furthermore, Nakajoh et al. (18) showed that ATRA inhibits elastase-induced apoptosis in BEAS-2B cells, A549 cells, and primary human tracheal epithelial cells. On the other hand, ATRA was reported to activate promoter activity of the IL-8 gene through a thioredoxin-dependent NF-κB activation in human airway epithelial cells (19) .
The biological response to RA is mediated by two classes of nuclear receptors. One group is the RA receptors (RARs) including three subtypes (RARα, RARβ, and RARγ), which are activated by ATRA and 9-cis RA. The second group is the retinoid X receptors (RXRs), also including three subtypes (RXRα, RXRβ, and RXRγ), which are activated by 9-cis RA only (20) . The effects of RARs on gene activity include both transactivation (19, 21, 22) and transrepression (23, 24, 25, 26) . To our knowledge, there are no reports regarding the effect of RA on the expression of eotaxin.
In the present study, we demonstrate that RA inhibits the expression of eotaxin and study the mechanisms responsible for the inhibitory effect of RA using a human bronchial epithelial cell line BEAS-2B.
LCMP-00289-2003.R1
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Materials and methods

Cell culture and reagents
BEAS-2B cells were cultured in DMEM/F12 medium supplemented with 10%
heat-inactivated fetal bovine serum, at 37°C in 5% CO 2 in humidified air. ATRA and 9-cis RA were dissolved in ethanol. IL-4 (a gift from Ono Pharmaceutical Company, Japan) and TNF-α (PeproTech, NJ) were dissolved in de-ionized distilled water. Genistein, a tyrosine kinase inhibitor and 12-O-tetradecanoylphorbol-13-acetate (TPA) were dissolved in dimethyl sulfoxide. In all experiments, ATRA and 9-cis RA were added 1 h before stimulation, and genistein was added 30 min before stimulation. Ethanol and dimethyl sulfoxide were diluted to final concentrations of less than 0.1% (v/v). All reagents were from Sigma unless otherwise indicated.
Construction of eotaxin promoter-luciferase reporter plasmids and AP1-luciferase reporter plamids
Eotaxin promoter-luciferase plasmids were constructed as previously reported (10) .
Briefly, a 1363-bp fragment of the promoter region of the eotaxin gene (site -1363 to -1) which contains CCAAT/enhancer-binding protein (C/EBP), activating protein-1 (AP-1), STAT6, and NF-κB response elements, was inserted into pGL3-Basic vector (Promega, WI) and the construct is referred to as pEotx.1363. Putative transcription factor binding sites in pEotx.1363 were mutated using the QuickChange site-directed mutagenesis kit (Stratagene, CA), using pEotx.1363 as a template. Constructs pEotx.M1 and M2 were synthesized by temperature cycling using site-mutated primers and PfuTurbo DNA polymerase (Stratagene)
as previously reported (10) . The pEotx.M1 has a mutated STAT6 response element (TTCCCTGGAA to AGCCCTGGAA). The pEotx.M2 has a mutated NF-κB response element (GGAATCTCCC to GGAATCTGGG). The pEotx.300 plasmid was constructed by LCMP-00289-2003.R1
-6 -5' end digestion of the pEotx.1363. The AP-1-luciferase reporter plasmid (AP1-Luc) is a pGL3-based vector in which two repeats of the consensus AP-1 site, TGAGTCA were inserted. The sequence of each plasmid insert DNA was determined by the dideoxy method using the fmol DNA Sequencing System (Promega).
Transient transfections and luciferase assays
BEAS-2B cells were seeded into six-well plates and allowed to grow to 50-70%
confluence. Cells were transfected with 4.5 µl of Fugene 6 transfection reagent (Roche Diagnostics, Germany), 1 µg of the plasmids (pEotx.1363, pEotx.M1, pEotx.M2, pEotx.300, or AP1-Luc), and 40 ng of renilla luciferase reporter vectors, and incubated in 2 ml of medium. Several concentrations of ATRA were added 24 h after transfection and cytokines were added 1 h after ATRA treatment. Six hours after cytokine treatment, cells were washed twice with PBS and solubilized with 100 µl of reporter passive lysis buffer (Promega).
Luciferase activity was measured using Dual-Luciferase Reporter Assay Systems (Promega) and a luminometer (Turner Designs, CA). Twenty µl of lysate was mixed with 100 µl of Luciferase Assay Reagent II. After measurement of firefly luciferase activity, 100 µl of Stop-and-Glo Reagent was added, then renilla luciferase activity was measured.
Measurement of eotaxin in the supernatant fluids
The concentrations of eotaxin were measured in the cell supernatant from BEAS-2B cells using a commercially available enzyme-linked immunoassay (ELISA) kit (Pharmingen, CA). The minimum concentration detected by this kit was 15.6 pg/ml.
Evaluation of eotaxin mRNA expression
Eotaxin mRNA was analyzed by reverse transcriptase polymerase chain reaction LCMP-00289-2003.R1
-7 -(RT-PCR). Four hours after stimulation with IL-4 or TNF-α, total RNA was extracted using a modification of the method of Chomczynski and Sacchi (27) . The RNA was reverse transcribed (RT) by using a Reverse Transcription Reagent (PE Applied Biosystems, CA).
Quantitative PCR was carried out in duplicate using an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, Foster City, CA) as described before (28) . The amounts of PCR product were quantified by the Sequence Detection System ® using ABI PRISM 7700.
Oligonucleotide PCR primer pairs and fluorescent probe for the eotaxin gene were designed from the published sequence using Primer Express software (PE Applied Biosystems) as 
Western blot analysis
Cytoplasmic ( was used at a dilution of 1:500 and after detecting pSTAT6, membranes were stripped and reprobed with anti -human STAT6 antibody to confirm that equal amounts of total STAT6 were transblotted.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear proteins (10 µg) were used in binding reactions as described previously (31).
Double-stranded oligonucleotides which contain both a STAT6 response element and an NF-κB response element that are partially overlapping (underlined) were designed and prepared as described previously; 5'-GGCTTCCCTGGAATCTCCCACA-3'
(TTCCCTGGAA for STAT6, GGAATCTCCC for NF-κB) (10) . Specificity of the complex was determined by prior addition of a 100-fold excess of unlabeled oligonucleotide. For supershift analysis, nuclear extracts were incubated on ice for 60 min with antisera raised to p50 (SC114-X), p65 (SC109-X), or STAT6 (SC621-X) (Santa Cruz) at 0.4 µg before the addition of a radiolabeled oligonucleotide. Reactions were separated by electrophoresis on 6% nondenaturing acrylamide gels in 0.25 X Tris-buffered EDTA. Gels were dried, and LCMP-00289-2003.R1
-10 -protein-DNA complexes were visualized by autoradiography.
Statistical analysis
Analyses of data were performed using StatView (Abacus Concepts, Berkeley, CA).
Data are expressed as the mean ± SE. Statistical differences were determined by ANOVA with Fisher's protected least significant difference test.
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Results
ATRA and 9-cis RA inhibited eotaxin release induced with IL-4 but not with TNF-α in BEAS-2B cells
To investigate the effect of retinoic acid on eotaxin release, various concentrations of ATRA (10 -10 , 10 -9 , 10 -8 , 10 -7 , and 10 -6 M) were added to BEAS-2B cells 1 h before stimulation for 24 h with IL-4 (10 ng/ml) or TNF-α (10 ng/ml). The supernatants were analyzed for eotaxin protein by ELISA. ATRA inhibited the release of eotaxin stimulated with IL-4 in a concentration-dependent manner and the inhibition was statistically significant at 10 -7 and 10 -6 M (Fig. 1A, P<0 .05). However, ATRA did not affect the release of eotaxin stimulated with TNF-α (Fig. 1B) . The effect of 9-cis RA on eotaxin release was also investigated using the same conditions. 9-cis RA showed a concentration-dependent inhibition on the release of eotaxin stimulated with IL-4 and the inhibition was statistically significant at 10 -7 and 10 -6 M (Fig. 1C, P<0 .05), but not with TNF-α (Fig. 1D ). ATRA and 9-cis RA did not affect the viability and number of cells, which was assessed using trypan blue exclusion (data not shown).
ATRA and 9-cis RA inhibited eotaxin mRNA expression induced with IL -4 but not with TNF-α
To investigate whether retinoic acid inhibits eotaxin release or production, we examined the effects of retinoic acid on eotaxin mRNA expression. Various concentrations of ATRA (10 -10 , 10 -8 , and 10 -6 M) were added to BEAS-2B cells 1 h before stimulation with IL-4 (10 ng/ml) or TNF-α (10 ng/ml). ATRA and 9-cis RA inhibited eotaxin mRNA expression induced with IL-4 in a concentration-dependent manner. Inhibition of eotaxin mRNA expression was statistically significant at 10 -8 and 10 -6 M by ATRA ( Fig. 2A, P<0 .05);
although of the same magnitude, the inhibitory effect of 9-cis RA was not statistically LCMP-00289-2003.R1
-12 -significant (Fig. 2B) . In contrast, neither ATRA nor 9-cisRA had any effect on TNF-α-induced eotaxin mRNA expression ( Fig. 2A and 2B ).
Effect of ATRA on IL-4 or TNF-α-induced activation of the eotaxin promoter
The results described above suggest that RA may attenuate the expression of eotaxin at the transcriptional level. To test this possibility, we performed transient transfection and luciferase driven reporter plasmid assays using a 1363-bp fragment of the eotaxin promoter, pEotx.1363. Both IL-4 (10 ng/ml) and TNF-α (10 ng/ml) increased luciferase activity in BEAS-2B cells transfected with the pEotx.1363 (Fig. 3A) . ATRA dose-dependently inhibited IL-4-induced activation of the eotaxin promoter and maximum inhibition was observed at 10 -6 M (approximately 51%, P<0.05). On the other hand, ATRA had no effect on TNF-α-induced activation of the eotaxin promoter (Fig. 3A) . Overlapping elements for STAT6 and NF-κB within the proximal eotaxin promoter have been shown to mediate the transcriptional induction by IL-4 and TNF-α, respectively (10) . A reporter containing the eotaxin promoter mutated at the binding site for STAT6, pEotx.M1, responded to TNF-α but not to IL-4 ( Fig. 3B) . In contrast, a reporter plasmid, pEotx.M2, which was mutated at the binding site of NF-κB, responded to IL-4 but not to TNF-α (Fig. 3C) . ATRA (10 -6 M)
significantly inhibited IL -4-induced activation of the pEotx.M2 (approximately 39%, P<0.05) (Fig. 3C ), but not TNF-α-induced activation of the pEotx.M1 (Fig. 3B) .
Effect of ATRA on IL-4-Induced phosphorylation and nuclear translocation of STAT6
The (Fig. 4, lower panel) . In the steady state (i.e. with no simulation), minimal phosphorylated STAT6 was detected (Fig. 4, upper 
AP-1 is not involved in ATRA-mediated transrepression
Several studies have demonstrated that ATRA inhibits AP-1 activity by RAR dependent mechanisms (23) (24) (26). The eotaxin promoter has AP-1 response elements (9) and pEotx.1363, which we used in luciferase assay of eotaxin promoter, also has an AP-1 response element. Taken together with the results described above, we speculated that ATRA may inhibit IL-4-induced transactivaion of the eotaxin promoter by inhibition of AP-1 activity without reducing DNA binding activity of STAT6. To investigate the role of AP-1, we performed transient transfection assays using an eotaxin promoter (site -300 to -1) luciferase (Fig. 8) . This result suggests that the inhibitory effect of ATRA on eotaxin promoter activity is independent of the AP-1 response element. We next sought to determine whether ATRA influences AP-1 activity in BEAS-2B cells. A transient transfection study was performed using the AP-1-dependent reporter plasmid, AP1-Luc, which contains two repeats of the consensus AP-1 site. ATRA had no effect on AP-1-dependent transactivation induced with TPA (100 nM) (Fig. 9) . These results further suggest that AP-1 is not involved in the ATRA-mediated transrepression of eotaxin gene expression in BEAS-2B cells. Neither IL-4 nor TNF-α was able to activate transcription of the AP1-Luc reporter in BEAS-2B cells suggesting that these cytokines do not activate AP-1 in bronchial epithelial cells (Fig. 9) .
Effect of ATRA on IL-4 or TNF-α-induced MCP-1 production
To determine whether the effect we observed was restricted to eotaxin, we examined the influence of ATRA on IL-4 or TNF-α-induced human monocyte chemotactic protein 1 (MCP-1) in BEAS-2B cells. ATRA significantly inhibited IL-4-induced MCP-1 production, which was measured in the cell supernatant by ELISA (1146.7±17.6 pg/ml with 10 ng/ml of IL-4 vs 648.0±5.8 ng/ml with IL-4 plus ATRA 10 -6 M, 43.5% inhibition, mean±SE, p<0.05).
In contrast to the case with eotaxin, ATRA also modestly inhibited TNF-α-induced MCP-1 production (1395.3.±27.8 pg/ml by 10 ng/ml of TNFα vs 1147.7±56. ATRA exerts its effect by binding to RARs, members of the nuclear receptor family, and 9cis-RA exerts its effect by binding RARs and RXRs (20) . In the present study, both ATRA and 9cis-RA showed the same effect on IL-4-induced eotaxin production, which indicates that RARs are most likely mediating the RA transrepression of the eotaxin gene.
RARs have three subtypes, designated as RARα, RARβ, and RARγ. We confirmed the Eotaxin is an important mediator of eosinophil trafficking into the airway and gastrointestinal tract and is also a potent activator of eosinophils (4, 52) . Our results demonstrate that RA has an inhibitory effect on IL-4-induced eotaxin production at least in part by inhibiting transcription. To assess the potential for clinical benefit of retinoic acid in eosinophilic inflammation, further studies will be needed in primary bronchial epithelial cells and using in vivo animal asthma models. However, these findings raise the possibility that ATRA and 9-cis RA may have a therapeutic value in reducing eosinophilic inflammation, which is important in the pathogenesis of mucosal diseases such as eosinophilic gastroenteritis, rhinitis and asthma. was detected using an antibody against specific Tyr-641phosphorylated STAT6 (upper panel).
Membranes were stripped and reprobed with an anti-pan-STAT6 antibody (lower panel).
Results are representative of four independent experiments. The data are presented as the mean ± SE. *, P<0.05 compared with IL-4 alone. 
